After Breast Implant, Anaplastic Large-cell Lymphoma May Be Under-recognized After Breast Implant, Anaplastic Large-cell Lymphoma May Be Under-recognized

Breast implant-associated anaplastic large-cell lymphoma is rare, but diagnoses seem to be increasing as both patients and clinicians become more aware of this complication, researchers in Pennsylvania say.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

ConclusionLow-dose TSEBT with adjuvant therapy results in adequate symptom palliation, comparable to standard-dose TSEBT. Low-dose TSEBT should be considered a standard treatment option in this population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionFrailty status assessment resulted in the identification of a group of unfit patients who had adequate tolerance to adjusted chemotherapy (R-choP) with good results.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionGiven the low rates of CNS relapse in this series, it is difficult to discern the impact of current risk stratification combined with intrathecal prophylaxis on outcomes. Our observation that many high-risk patients did not receive prophylaxis while many low-risk patients received prophylaxis emphasizes the need for a standardized approach.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Dorfman T, Neymark M, Begal J, Kluger Y Abstract BACKGROUND: Enlarged lymph nodes (ELN) pose a great diagnostic challenge. They may represent the first clinical finding of a hematologic disease or other malignancy and may be an indication of a wide range of infectious and non-infectious diseases. Because many patients undergo percutaneous biopsy, surgical excisional biopsy is not often considered. OBJECTIVES: To analyze indications for a patient's referral for surgical biopsy of ELN and diagnostic steps to follow until referral, and to determine the number of ELN. METHODS: A retrospective study was...
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
We describe a case of MTX-LPD of the stomach. After treatment with methotrexate for rheumatoid arthritis, the patient developed left cervical lymphadenopathy and an ulcerative lesion in the stomach, which was presumed to be a mucosa-associated lymphoid tissue (MALT) lymphoma. However, we suspected MTX-LPD, based on the clinical course and the positivity of in situ hybridization for the detection of the Epstein-Barr encoding region. After the cessation of MTX, the left cervical lymphadenopathy and the gastric lesion disappeared. This is first report of gastric MTX-LPD that was presumed to be MALT lymphoma. PMID: 3042943...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
ConclusionsPrimary central nervous system lymphoma is rare, even more so in the cerebellum. However, the overall incidence of primary central nervous system lymphoma is rising in both immunocompromised and immunocompetent patients. The highly aggressive nature of primary central nervous system lymphoma necessitates timely diagnosis and intervention. In this report, we review the available literature for a better understanding of the pathophysiology and management of primary central nervous system lymphoma. To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphom...
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
The ground-breaking study, led by the Leukemia&Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Authors: Shim H, Jang S, Huh J, Yoon DH, Suh C, Park CJ Abstract Assessment of bone marrow (BM) involvement in peripheral T-cell lymphoma, not otherwise specified (PTCL) is straightforward in cases of extensive involvement but difficult in cases of minimal to partial involvement. We evaluated the usefulness of CD3 as an immunohistochemical marker for assessing BM involvement in PTCL patients. BM biopsies of 92 PTCL patients were immunohistochemically stained for CD3, CD4, CD8, CD20, and CD56, and evaluated by two hematopathologists. CD3 positivity was graded according to the proportion of CD3-positive cells and the...
Source: Annals of Laboratory Medicine - Category: Laboratory Medicine Tags: Ann Lab Med Source Type: research
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Health | Hematology | Lymphoma | Plastic Surgery